Clinical Trials · NCT03288740
A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 36
- Start date
- Sep 2017
- Locations
- 1 site, China
- Primary endpoint
- Area under the semaglutide plasma concentration time curve at steady state (semaglutide 0.5 mg)